Real-world efficacy of Lenvatinib/Pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers

Key Points

• The central aim is to evaluate the efficacy and safety of Lenvatinib and Pembrolizumab in treating anaplastic thyroid carcinoma.
• Conducted at two Italian referral centers
• Analyzed case series of patients receiving L+P therapy
• Evaluated the prognostic value of the CONUT score
• Confirmed the efficacy of Lenvatinib/Pembrolizumab combination therapy
• Identified the CONUT score as a significant prognostic factor for treatment outcomes